Zobrazeno 1 - 10
of 666
pro vyhledávání: '"David M Livermore"'
Autor:
Julia Notter, Salome N. Seiffert, Maria Zimmermann-Kogadeeva, Anja Bösch, Robert Wenger, Carol Strahm, Manuel Frischknecht, David M. Livermore, Baharak Babouee Flury
Publikováno v:
BMC Infectious Diseases, Vol 22, Iss 1, Pp 1-7 (2022)
Abstract Background Data on antimicrobial resistance mechanisms are scanty for Cedecea spp., with very variable antibiotic resistance patterns documented. Here we report the first in vivo resistance evolution of a C. davisae clinical isolate in a pat
Externí odkaz:
https://doaj.org/article/6f533dfcffe34b95b6dc490e2147bef1
Autor:
Juliet High, Virve I. Enne, Julie A. Barber, David Brealey, David A. Turner, Robert Horne, Mark Peters, Zaneeta Dhesi, Adam P. Wagner, Alyssa M. Pandolfo, Sue Stirling, Charlotte Russell, Justin O’Grady, Ann Marie Swart, Vanya Gant, David M. Livermore, INHALE Study Group
Publikováno v:
Trials, Vol 22, Iss 1, Pp 1-12 (2021)
Abstract Background Hospital-acquired and ventilator-associated pneumonias (HAP and VAP) are common in critical care and can be life-threatening. Rapid microbiological diagnostics, linked to an algorithm to translate their results into antibiotic cho
Externí odkaz:
https://doaj.org/article/22aeafa42d3847b58a72a4cf0022fa7e
Autor:
Alyssa M. Pandolfo, Robert Horne, Yogini Jani, Tom W. Reader, Natalie Bidad, David Brealey, Virve I. Enne, David M. Livermore, Vanya Gant, Stephen J. Brett, the INHALE WP2 Study Group
Publikováno v:
Antimicrobial Resistance and Infection Control, Vol 10, Iss 1, Pp 1-8 (2021)
Abstract Background Rapid molecular diagnostic tests to investigate the microbial aetiology of pneumonias may improve treatment and antimicrobial stewardship in intensive care units (ICUs). Clinicians’ endorsement and uptake of these tests is cruci
Externí odkaz:
https://doaj.org/article/e3b60ce7363d475892d9a69a720d9f0a
Publikováno v:
Frontiers in Public Health, Vol 10 (2022)
Externí odkaz:
https://doaj.org/article/c022d6a0cccf42bab4f20b78f4813a5f
Autor:
Andrew M Wilson, Allan B Clark, Anthony Cahn, Edwin R Chilvers, William Fraser, Matthew Hammond, David M Livermore, Toby M Maher, Helen Parfrey, Ann Marie Swart, Susan Stirling, David Thickett, Moira Whyte
Publikováno v:
Efficacy and Mechanism Evaluation, Vol 8, Iss 9 (2021)
Background: Idiopathic pulmonary fibrosis is an irreversible fibrosing lung disorder with a poor prognosis. Current treatments slow the rate of decline in lung function and may influence survival, but they have a significant side-effect profile and s
Externí odkaz:
https://doaj.org/article/eac2fcbe27b44ad5b2fc818f25be3374
Autor:
Matthew Hammond, Allan B. Clark, Anthony P. Cahn, Edwin R. Chilvers, William Duncan Fraser, David M. Livermore, Toby M. Maher, Helen Parfrey, Ann Marie Swart, Susan Stirling, David Thickett, Moira Whyte, Andrew Wilson
Publikováno v:
Trials, Vol 19, Iss 1, Pp 1-12 (2018)
Abstract Background We hypothesise, based upon the findings from our previous trial, that the addition of co-trimoxazole to standard therapy is beneficial to patients with moderate to severe idiopathic pulmonary fibrosis (IPF). We aim to investigate
Externí odkaz:
https://doaj.org/article/cbc90e7411364a5a8bb2ccb0d095d0b6
Autor:
Ahuva Cern, Yaelle Bavli, Atara Hod, Daniel Zilbersheid, Shazad Mushtaq, Ayelet Michael-Gayego, Dinorah Barasch, Yael Feinstein Rotkopf, Allon E. Moses, David M. Livermore, Yechezkel Barenholz
Publikováno v:
Pharmaceutics, Vol 13, Iss 12, p 2186 (2021)
Antibiotic resistance is a global health threat. There are a few antibiotics under development, and even fewer with new modes of action and no cross-resistance to established antibiotics. Accordingly, reformulation of old antibiotics to overcome resi
Externí odkaz:
https://doaj.org/article/88f8dd726fd14c7a8535af5349bf0ad5
Aztreonam/avibactam is being developed on the rationale that aztreonam evades metallo-β-lactamases (MBLs) whilst avibactam protects aztreonam against co-produced serine β-lactamases. This study measured the activity of aztreonam/avibactam against M
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eaf38a0725e5c2d961585330d6b519a3
https://ueaeprints.uea.ac.uk/id/eprint/91357/
https://ueaeprints.uea.ac.uk/id/eprint/91357/
Publikováno v:
Journal of Antimicrobial Chemotherapy. 77:1916-1922
Objectives Combinations of PBP3-active β-lactams with developmental diazabicyclooctanes (DBOs), e.g. zidebactam, remain active against many MBL producers via an enhancer effect. We explored how this activity is affected by inoculum. Materials and me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06094fed32d060f6572af2251ee1f136
https://doi.org/10.1093/jac/dkac108
https://doi.org/10.1093/jac/dkac108
Autor:
Virve I, Enne, Alp, Aydin, Rossella, Baldan, Dewi R, Owen, Hollian, Richardson, Federico, Ricciardi, Charlotte, Russell, Brenda O, Nomamiukor-Ikeji, Ann-Marie, Swart, Juliet, High, Antony, Colles, Julie, Barber, Vanya, Gant, David M, Livermore, Justin, O'Grady, David, Turner
BackgroundCulture-based microbiological investigation of hospital-acquired or ventilator-associated pneumonia (HAP or VAP) is insensitive, with aetiological agents often unidentified. This can lead to excess antimicrobial treatment of patients with s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0f2183271059fc2b6dff702a0b5dc2f
https://ueaeprints.uea.ac.uk/id/eprint/82615/
https://ueaeprints.uea.ac.uk/id/eprint/82615/